ALFA Finder
16:04 IST
BSE
Other Announcement
Venus Remedies Other Announcement
Venus Remedies relayed social media posts about a SEBI special window for re-lodging physical share transfer requests. The notice carries no monetary event.
Venus Remedies Ltd
- Share price
- ₹1,447.90
- Market cap
- ₹1,935 Cr
- Revenue (annual)
- ₹769.6 Cr
- Net profit (annual)
- ₹102.8 Cr
- P/E (TTM)
- 15.9×Sector 43.8×
- Promoter holding
- 41.76%+0.00% QoQ
- FII holding
- 3.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 7Financial Results 4Regulatory Approval 2Management Change 2Board Meeting Date 2Annual General Meeting 2Dividend 1Board Meeting Outcome 1
Time
7 announcements with these filters
09:31 IST
BSE
Other Announcement
Venus Remedies Other Announcement
Venus Remedies Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
17:33 IST
NSE
Other Announcement
Venus Remedies Other Announcement
Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.
17:33 IST
NSE
Other Announcement
Venus Remedies Other Announcement
Venus Remedies Limited has informed the exchanges about its social media posts regarding a special window for the re-lodgement of physical share transfer requests.
17:41 IST
BSE
Other Announcement
Venus Remedies Other Announcement
Venus Remedies informed the exchanges about their social media communications regarding a special window for re-lodgement of physical share transfer requests.
16:24 IST
BSE
Other Announcement
Venus Remedies Other Announcement
Venus Remedies secured the renewal of its DSIR in-house R&D recognition for its research center. The certification supports ongoing development of novel antimicrobial resistance treatments.
17:27 IST
BSE
Other Announcement
Venus Remedies Other Announcement
Venus Remedies shared social media links to encourage shareholders to update KYC details. This routine compliance effort ensures regulatory alignment and investor records accuracy.